Getinge (OTCMKTS:GNGBY) Reaches New 1-Year High – Should You Buy?

Getinge (OTCMKTS:GNGBY) shares reached a new 52-week high on Thursday. The stock traded as high as $25.9950 and last traded at $25.9950, with a volume of 249 shares. The stock had previously closed at $25.51.

Analyst Upgrades and Downgrades

GNGBY has been the subject of a number of research analyst reports. Pareto Securities lowered Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 24th. UBS Group initiated coverage on shares of Getinge in a report on Wednesday, September 2nd. They set a “hold” rating on the stock. Nordea Equity Research lowered Getinge from a “buy” rating to a “hold” rating in a report on Monday, August 31st. Finally, Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. Four research analysts have rated the stock with a Hold rating. According to MarketBeat, Getinge presently has an average rating of “Hold”.

Getinge Stock Up 1.9%

The stock has a fifty day simple moving average of $25.02 and a two-hundred day simple moving average of $22.52. The firm has a market cap of $7.08 billion, a PE ratio of 24.76 and a beta of 0.95. The company has a current ratio of 1.31, a quick ratio of 0.74 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY) last posted its quarterly earnings data on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. The company had revenue of $894.87 million during the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%. As a group, sell-side analysts expect that Getinge will post 1.38 EPS for the current fiscal year.

About Getinge

Getinge AB is a Swedish medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support surgical procedures, intensive care, infection prevention and the manufacture of pharmaceuticals and other medical products.

The company’s portfolio includes operating room and surgical workflow systems, anesthesia and ventilation equipment, intensive care solutions, cardiovascular devices, sterilization and disinfection systems, and equipment for laboratories and pharmaceutical production.